ghk-cu fda approved drug adds non-injectable back to Category 1. FDA Thursday re-added non-injectable GHK-Cu to Category 1 of the 503A bulks process after the nomination was withdrawn from further review. Injectable GHK-Cu remains GHK-Cu (100mg) Research Peptide |

BPC-157 is most commonly used for soft-tissue injury recovery (tendons, ligaments, muscle), chronic tendinopathy, joint discomfort, gut health concerns, and post-surgical tissue repair

Examine.com reports most benefits are from animal studies

In research it is studied for sleep-architecture pathway research, hypothalamic-pituitary axis modulation, and stress-response signaling

Patients have the right to make informed choices, and informed choice requires accurate information

Researchers continue to investigate its potential effects on tendon structures, where coordinated cellular activity and matrix reorganization play critical roles